Table 2.
Prognostic and predictive value of different genetic tests in breast cancer
| ASCO 2016 | NCCN 2016 | ESMO 2015 | SEOM 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | Prognosis | CT benefit prediction | ||||
| 5 years | 10 years | 5 years | 10 years | 5 years | 10 years | ||||||
| Oncotype DX® | Yes | NA | Yes | Yes | Yes | +++ | +++ | Yes | IA (low RS) IB (other RSs) |
IB | IA (low RS) IB (other RSs) |
| Prosigna® | Yes | Yes | Yes | Yes | NA | ++ | ++ | Yes | IB | IB | NA |
| MammaPrint® | Yes | – | – | Yes | NA | +++ | NA | Yes | IB | NA | NA |
| EndoPredict® | Yes | Yes | Yes | Yes | NA | ++ | ++ | Yes | IB | IB | NA |
ASCO American Society of Clinical Oncology, CT chemotherapy, ESMO European Society for Medical Oncology, NA not available, NCCN National Comprehensive Cancer Network, RS Recurrence Score, SEOM Spanish Society of Medical Oncology